Human Vaccines & Immunotherapeutics
ISSN: 2164-5515 (Print) 2164-554X (Online) Journal homepage: http://www.tandfonline.com/loi/khvi20
Acceptability of live attenuated influenza vaccine by vaccine providers in Quebec, Canada Eve Dubé, Dominique Gagnon, Marilou Kiely, Nicole Boulianne & Monique Landry To cite this article: Eve Dubé, Dominique Gagnon, Marilou Kiely, Nicole Boulianne & Monique Landry (2015) Acceptability of live attenuated influenza vaccine by vaccine providers in Quebec, Canada, Human Vaccines & Immunotherapeutics, 11:4, 956-960, DOI: 10.1080/21645515.2015.1009816 To link to this article: http://dx.doi.org/10.1080/21645515.2015.1009816
Accepted author version posted online: 09 Mar 2015.
Submit your article to this journal
Article views: 34
View related articles
View Crossmark data
Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=khvi20 Download by: [University of Pennsylvania]
Date: 05 November 2015, At: 20:37
RESEARCH PAPER Human Vaccines & Immunotherapeutics 11:4, 956--960; April 2015; © 2015 Taylor & Francis Group, LLC
Acceptability of live attenuated influenza vaccine by vaccine providers in Quebec, Canada Eve Dub e1,2,3,*, Dominique Gagnon1, Marilou Kiely1, Nicole Boulianne1,2, and Monique Landry4 1
Quebec Institute of Public Health; Quebec, Canada; 2CHU of Quebec Research Center; Quebec, Canada; 3Laval University; Quebec, Canada; 4Quebec Ministry of Health and Social Services; Montreal, Canada
Keywords: acceptability, Flumist, influenza, intranasal, live attenuated influenza vaccine, vaccination
Downloaded by [University of Pennsylvania] at 20:37 05 November 2015
Abbreviations: CLSC, Center local de services communautaires, local community service center; KAP, knowledge, attitudes and practices; LAIV, live attenuated influenza vaccine; TIV, trivalent inactivated influenza vaccine
A live attenuated influenza vaccine (LAIV) was offered during the 2012-13 influenza season in Quebec, Canada, to children aged between 2 and 17 years with chronic medical conditions. Despite the offer, uptake of the vaccine was low. We assessed the perceptions and opinions about seasonal influenza vaccination and LAIV use among vaccine providers who participated in the 2012-13 campaign. More than 70% of them thought that LAIV was safe and effective and more than 90% considered that the vaccine was well-received by parents and healthcare professionals. According to respondents, the most frequent concerns of parents about LAIV were linked to vaccine efficacy. LAIV is well-accepted by vaccine providers involved in influenza vaccination clinics, but more information about the vaccine and the recommendations for its use are needed to increase vaccine uptake.
Introduction In Canada, immunization programs are under the responsibility of provinces and territories. In the province of Quebec, influenza vaccination is recommended for people at high risk of serious complications as well as for their contacts.1 The Quebec publicly funded influenza vaccination program targets infants aged 6–23 months; adults aged 60 years; people having frequent contact with people at higher risk of complications from infection (e.g. healthcare professionals) and individuals aged 2 years with chronic medical conditions (e.g., cardiac and pulmonary disorders, diabetes, immune-compromised conditions, renal disease, asthma, etc.).2 Trivalent inactivated influenza vaccines (TIV), which are administered intramuscularly, are routinely used in Quebec to vaccinate children and adolescents against influenza. However, since 2010, a live attenuated influenza vaccine (LAIV) administered by intranasal spray (FluMistÒ ) has been approved for use in healthy children aged between 2 and 17 years in Canada.1 In 2012, the Quebec Immunization Committee recommended the preferential use of LAIV over TIV for all children aged between 2 and 17 years, including children with underlying chronic medical conditions without immunosuppression.3 In the fall of 2012, the Quebec Ministry of Health bought 100,000 doses of LAIV. Given the limited quantity of doses, only children aged between 2 and 17 years with chronic medical conditions were targeted to receive LAIV and no large promotional activities were made. In the early weeks of the 2012–13
vaccination campaign, due to a lack of demand, the recommendations on LAIV use were expanded to include all children aged between 2 and 17 years targeted by the publicly-funded influenza vaccination program. However, only half of the available doses were administered during the vaccination campaign. Vaccine providers’ recommendations are an important determinant of vaccine acceptance among patients.4-7 For instance, in a review published in 2012, nurses’ knowledge and attitudes about influenza vaccine were highly associated with their own vaccine uptake, their intention to recommend the vaccine to their patients and the vaccine uptake of their patients.8 Since LAIV will be used routinely in future seasonal influenza vaccination campaigns, a survey was conducted to explore vaccine providers’ knowledge, attitudes and practices (KAP) regarding seasonal influenza immunization and use of LAIV.
Results The survey invitation was sent to 427 vaccine providers and 314 of them completed it (76% filled out the questionnaire online and the others completed the paper version). The respondents’ socio demographic and professionals’ characteristics are presented in Table 1. Almost all respondents (94%) were nurses, and the majority were working in local community service centers (known by their French acronym CLSCs) (79%). Fifty one percent (51%) of the respondents had more than 20 years of practice.
*Correspondence to: Eve Dube; Email: [email protected] Submitted: 10/07/2014; Revised: 12/11/2014; Accepted: 12/24/2014 http://dx.doi.org/10.1080/21645515.2015.1009816
956
Human Vaccines & Immunotherapeutics
Volume 11 Issue 4
Downloaded by [University of Pennsylvania] at 20:37 05 November 2015
Table 1. Characteristics of survey participants
Main practice place Community health center Medical clinic Family Medical Unit/Family Medical Group Hospital outpatient clinic Long-term care facilities Dispensary Other Type of profession Physician Nurse Administrative staff Other Number of years of practice
ISSN: 2164-5515 (Print) 2164-554X (Online) Journal homepage: http://www.tandfonline.com/loi/khvi20
Acceptability of live attenuated influenza vaccine by vaccine providers in Quebec, Canada Eve Dubé, Dominique Gagnon, Marilou Kiely, Nicole Boulianne & Monique Landry To cite this article: Eve Dubé, Dominique Gagnon, Marilou Kiely, Nicole Boulianne & Monique Landry (2015) Acceptability of live attenuated influenza vaccine by vaccine providers in Quebec, Canada, Human Vaccines & Immunotherapeutics, 11:4, 956-960, DOI: 10.1080/21645515.2015.1009816 To link to this article: http://dx.doi.org/10.1080/21645515.2015.1009816
Accepted author version posted online: 09 Mar 2015.
Submit your article to this journal
Article views: 34
View related articles
View Crossmark data
Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=khvi20 Download by: [University of Pennsylvania]
Date: 05 November 2015, At: 20:37
RESEARCH PAPER Human Vaccines & Immunotherapeutics 11:4, 956--960; April 2015; © 2015 Taylor & Francis Group, LLC
Acceptability of live attenuated influenza vaccine by vaccine providers in Quebec, Canada Eve Dub e1,2,3,*, Dominique Gagnon1, Marilou Kiely1, Nicole Boulianne1,2, and Monique Landry4 1
Quebec Institute of Public Health; Quebec, Canada; 2CHU of Quebec Research Center; Quebec, Canada; 3Laval University; Quebec, Canada; 4Quebec Ministry of Health and Social Services; Montreal, Canada
Keywords: acceptability, Flumist, influenza, intranasal, live attenuated influenza vaccine, vaccination
Downloaded by [University of Pennsylvania] at 20:37 05 November 2015
Abbreviations: CLSC, Center local de services communautaires, local community service center; KAP, knowledge, attitudes and practices; LAIV, live attenuated influenza vaccine; TIV, trivalent inactivated influenza vaccine
A live attenuated influenza vaccine (LAIV) was offered during the 2012-13 influenza season in Quebec, Canada, to children aged between 2 and 17 years with chronic medical conditions. Despite the offer, uptake of the vaccine was low. We assessed the perceptions and opinions about seasonal influenza vaccination and LAIV use among vaccine providers who participated in the 2012-13 campaign. More than 70% of them thought that LAIV was safe and effective and more than 90% considered that the vaccine was well-received by parents and healthcare professionals. According to respondents, the most frequent concerns of parents about LAIV were linked to vaccine efficacy. LAIV is well-accepted by vaccine providers involved in influenza vaccination clinics, but more information about the vaccine and the recommendations for its use are needed to increase vaccine uptake.
Introduction In Canada, immunization programs are under the responsibility of provinces and territories. In the province of Quebec, influenza vaccination is recommended for people at high risk of serious complications as well as for their contacts.1 The Quebec publicly funded influenza vaccination program targets infants aged 6–23 months; adults aged 60 years; people having frequent contact with people at higher risk of complications from infection (e.g. healthcare professionals) and individuals aged 2 years with chronic medical conditions (e.g., cardiac and pulmonary disorders, diabetes, immune-compromised conditions, renal disease, asthma, etc.).2 Trivalent inactivated influenza vaccines (TIV), which are administered intramuscularly, are routinely used in Quebec to vaccinate children and adolescents against influenza. However, since 2010, a live attenuated influenza vaccine (LAIV) administered by intranasal spray (FluMistÒ ) has been approved for use in healthy children aged between 2 and 17 years in Canada.1 In 2012, the Quebec Immunization Committee recommended the preferential use of LAIV over TIV for all children aged between 2 and 17 years, including children with underlying chronic medical conditions without immunosuppression.3 In the fall of 2012, the Quebec Ministry of Health bought 100,000 doses of LAIV. Given the limited quantity of doses, only children aged between 2 and 17 years with chronic medical conditions were targeted to receive LAIV and no large promotional activities were made. In the early weeks of the 2012–13
vaccination campaign, due to a lack of demand, the recommendations on LAIV use were expanded to include all children aged between 2 and 17 years targeted by the publicly-funded influenza vaccination program. However, only half of the available doses were administered during the vaccination campaign. Vaccine providers’ recommendations are an important determinant of vaccine acceptance among patients.4-7 For instance, in a review published in 2012, nurses’ knowledge and attitudes about influenza vaccine were highly associated with their own vaccine uptake, their intention to recommend the vaccine to their patients and the vaccine uptake of their patients.8 Since LAIV will be used routinely in future seasonal influenza vaccination campaigns, a survey was conducted to explore vaccine providers’ knowledge, attitudes and practices (KAP) regarding seasonal influenza immunization and use of LAIV.
Results The survey invitation was sent to 427 vaccine providers and 314 of them completed it (76% filled out the questionnaire online and the others completed the paper version). The respondents’ socio demographic and professionals’ characteristics are presented in Table 1. Almost all respondents (94%) were nurses, and the majority were working in local community service centers (known by their French acronym CLSCs) (79%). Fifty one percent (51%) of the respondents had more than 20 years of practice.
*Correspondence to: Eve Dube; Email: [email protected] Submitted: 10/07/2014; Revised: 12/11/2014; Accepted: 12/24/2014 http://dx.doi.org/10.1080/21645515.2015.1009816
956
Human Vaccines & Immunotherapeutics
Volume 11 Issue 4
Downloaded by [University of Pennsylvania] at 20:37 05 November 2015
Table 1. Characteristics of survey participants
Main practice place Community health center Medical clinic Family Medical Unit/Family Medical Group Hospital outpatient clinic Long-term care facilities Dispensary Other Type of profession Physician Nurse Administrative staff Other Number of years of practice
